WANDA BEARING
920002
HENDERA
831152
LINGOOD
833284
4
WUHAN LAND
830779
5
TECHVISION
832876
US Stock MarketDetailed Quotes
ALGS Aligos Therapeutics
- 17.750
- +0.420+2.42%
Close Feb 26 16:00 ET
- 17.710
- -0.040-0.23%
Post 20:01 ET
63.69MMarket Cap-2.45P/E (TTM)
18.750High17.386Low268.70KVolume17.630Open17.330Pre Close4.84MTurnover14.65%Turnover RatioLossP/E (Static)3.59MShares46.80052wk High1.27P/B32.56MFloat Cap6.76052wk Low--Dividend TTM1.83MShs Float937.748Historical High--Div YieldTTM7.87%Amplitude6.760Historical Low18.021Avg Price1Lot Size
About Aligos Therapeutics Company
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.
Company Profile
SymbolALGS
Company NameAligos Therapeutics
Listing DateOct 16, 2020
Issue Price15.00
Founded2018
CEODr. Lawrence M. Blatt,PhD
MarketNASDAQ
Employees66
Fiscal Year Ends12-31
Address1 Corporate Drive,2nd floor
CitySouth San Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080
Phone1-800-466-6059
Websitehttp://www.aligos.com
Company Executives
- Name
- Position
- Salary
- Dr. Lawrence M. Blatt,PhD
- President, Chairman of the Board and Chief Executive Officer
- 1.34M
- Lesley Ann Calhoun
- Chief Operating Officer, Executive Vice President, Chief Financial Officer and Principal Accounting Officer
- --
- Julian A. Symons, D.Phil.
- Executive Vice President and Chief Scientific Officer
- 836.32K
- Margarita Chavez, J.D.
- Director
- --
- Dr. Heather Elizabeth Preston, M.D.
- Director
- --
- Dr. Bridget A. Martell, M.D.
- Independent Director
- 52.90K
- James Scopa
- Independent Director
- 67.90K
- Dr. K. Peter Hirth, PhD
- Independent Director
- 60.40K
- Carole L. Nuechterlein, J.D.
- Independent Director
- 12.90K
Trending Stocks
Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio?
Moo Live
Jan 30 03:25
FOMC Press Conference, January 29, 2025